Mylan paying $465M to settle claims it overcharged for EpiPens

2017-08-17 | The Hill: Healthcare Policy

Mylan has finalized a $465 million settlement with the federal government over claims the pharmaceutical company overcharged Medicaid for the EpiPen, an emergency allergy treatment.Thursday’s announcement puts to rest claims that the drugmaker...

Link to document